Research program Live corpus

Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.

PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,351 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

Explore Platform → See latest papers

40,351 Papers indexed

1,440 Papers AI scored

40,351 Ranked papers

100.0% Coverage

Featured discovery ● Live

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

AI Score 79.80 Active signal

Grade A

Final score 88.16

Narrative velocity Not calculated

Confidence Building

CHIP-AML22 is a multinational pediatric de novo AML trial protocol integrating risk-adapted therapy, randomized gemtuzumab ozogamicin and consolidation-course comparisons, subgroup-specific quizartinib, and toxicity-reduction measures.

Read full analysis →

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE

↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing

TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Published Jun 20, 2026

Journal Trials

88.16 Ranking score

A grade PMID 42321916

View analysis →

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

Published Sep 03, 2026

Journal JAMA oncology

87.88 Ranking score

A grade PMID 42690647

View analysis →

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Published Jul 01, 2026

Journal The Lancet. Oncology

87.73 Ranking score

A grade PMID 42372741

View analysis →

Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human.

Published May 30, 2026

Journal Oncoimmunology

87.38 Ranking score

A grade PMID 42216567

View analysis →

Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.

Published Mar 31, 2026

Journal BMJ (Clinical research ed.)

87.15 Ranking score

A grade PMID 41916649

View analysis →

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

Published May 18, 2026

Journal EClinicalMedicine

86.97 Ranking score

A grade PMID 42382416

View analysis →

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

Published May 18, 2026

Journal The Lancet. Child & adolescent health

85.99 Ranking score

A grade PMID 42150584

View analysis →

Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.

Published Sep 17, 2026

Journal The New England journal of medicine

85.54 Ranking score

B grade PMID 42748428

View analysis →

Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma.

Published Feb 20, 2026

Journal bioRxiv : the preprint server for biology

85.22 Ranking score

A grade PMID 41756844

View analysis →

A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

Published Sep 21, 2026

Journal Blood cancer discovery

85.08 Ranking score

A grade PMID 42765973

View analysis →

T-cell receptor-engineered T-cell therapy using a glypican-3-specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2-positive glypican-3-expressing cancers.

Published Jun 26, 2026

Journal Cancer letters

85.07 Ranking score

A grade PMID 42362103

View analysis →

Gilteritinib and chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial.

Published Jul 14, 2026

Journal Blood advances

84.86 Ranking score

A grade PMID 42101908

View analysis →

LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-12 10:15 AM

1 Interventions to reduce paediatric cancer treatment abandonment in low-income and middle-income countries: a systematic review and meta-analysis. The Lancet. Global health — Nov 12, 2026 2 Paediatric cancer treatment abandonment: multifaceted solutions required. The Lancet. Global health — Nov 12, 2026 3 Conjunctival inflammatory myofibroblastic tumour in infancy: diagnostic challenges and sequential histopathological evolution. BMJ case reports — Nov 12, 2026 4 Genome-wide association study meta-analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk. Cell genomics — Nov 12, 2026 5 Getting on the "same page": Couples' experiences communicating about hereditary cancer risk and family building decisions. Journal of psychosocial oncology — Nov 12, 2026 6 SPROUT Guidelines for Molecular Profiling for Children with Solid Tumors: A Consensus Recommendation from the American Association for Cancer Research. Clinical cancer research : an official journal of the American Association for Cancer Research — Nov 12, 2026 7 Association of medical play therapy with psychological resilience during chemotherapy in children with malignant lymphoma: a propensity score-weighted retrospective cohort study. Psychology, health & medicine — Nov 12, 2026 8 Expression patterns of hypoxia signaling pathway genes and their association with clinical biochemical parameters in acute myeloid leukemia patients of Assam: A case control study. Molecular biology reports — Nov 12, 2026

WHAT THE AI SEES TODAY

Live pediatric oncology intelligence

● Live

↗

Therapeutic signal strength is updating across newly scored pediatric oncology literature.

✦

Mechanism clusters are forming around tumor biology, immune response, targeted therapy, treatment resistance, and drug repurposing.

⌁

Daily literature intake feeds the ranking engine and refreshes study-design, human-relevance, and therapeutic-relevance scores.

●

40,351 pediatric cancer records are currently visible under this search.

PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40351 results

Solitary intraoral pyogenic granuloma in neurofibromatosis type 1: diagnostic conundrum.

PMID 40615127 Published: 2025-07-03 Ingested: 2026-08-02 12:04 AM BMJ case reports

AI -

Standard 44.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 44.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

Brainstem cavernous malformations in pediatrics: case report and literature review.

PMID 40609104 Published: 2025-01-01 Ingested: 2026-08-02 12:03 AM Cirugia y cirujanos

AI -

Standard 44.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 44.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

Favourable maternal and neonatal outcomes following expectant management of a giant placental chorangioma.

PMID 40592600 Published: 2025-07-01 Ingested: 2026-08-02 12:04 AM BMJ case reports

AI -

Standard 44.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 44.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

Meigs syndrome in low-resource setting: a pediatric case report.

PMID 40585466 Published: 2025-06-27 Ingested: 2026-08-02 12:04 AM Oxford medical case reports

AI -

Standard 44.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 44.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

Case Report: First case of a pediatric laryngeal inflammatory rhabdomyoblastic tumor-diagnostic dilemma and insights into the conservative management of a residual lesion.

PMID 40567521 Published: 2025-06-11 Ingested: 2026-08-02 12:03 AM Frontiers in pediatrics

AI -

Standard 44.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 44.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

Thyroglossal duct cyst in the suprasternal region in an adolescent.

PMID 40562544 Published: 2025-06-25 Ingested: 2026-08-02 12:04 AM BMJ case reports

AI -

Standard 44.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 44.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

A Rare Case of Cervical Solitary Fibrous Tumor in a Pediatric Patient: Case Report and Literature Review.

PMID 40559210 Published: 2025-06-01 Ingested: 2026-08-02 12:04 AM NeuroSci

AI -

Standard 44.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 44.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

De novo myeloid sarcoma of the oral cavity in early adolescence: an uncommon presentation with severe congenital neutropenia.

PMID 40555537 Published: 2025-06-24 Ingested: 2026-08-02 12:04 AM BMJ case reports

AI -

Standard 44.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 44.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

Thoracic Aneurysmal Bone Cyst with Spinal Cord Compression Managed with Arterial Embolization: A Case Report.

PMID 40537001 Published: 2025-06-20 Ingested: 2026-08-02 12:04 AM JBJS case connector

AI -

Standard 44.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 44.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

Neuropathologic Findings in Lennox-Gastaut Syndrome (SCN2A-Related): A Case Report and Review of Literature.

PMID 40536032 Published: 2025-06-19 Ingested: 2026-08-02 12:04 AM Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society

AI -

Standard 44.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 44.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

Surgical excision of Genitourinary neurofibromatosis complicated by enlarged scrotum and penis: A case report.

PMID 40534603 Published: 2025-05-29 Ingested: 2026-08-02 12:04 AM Urology case reports

AI -

Standard 44.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 44.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

Shared chromatin remodeling mutations drive concurrent rhabdomyosarcoma and leukemia in a pediatric patient.

PMID 40522594 Published: 2025-06-16 Ingested: 2026-08-02 12:04 AM Discover oncology

AI -

Standard 44.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 44.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

Page 3173 of 3363

Open the Research
Intelligence Map

Finding therapies hidden in 40,351 pediatric cancer papers.

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Ranked Discovery Journal Articles

Database feed

All ranked pediatric cancer papers

AI-assisted research information

Open the Research Intelligence Map